cance of the level of serum 25-hydroxyvitamin D 3 D 3 ] and interleukin (IL)-6 in serum prior to and after immunoglobulin treatment in children suffering from Kawasaki disease in order to provide a reference for the successful treatment of Kawasaki disease in children. From February, 2013 to February, 2015 patients with Kawasaki disease were enrolled in the observation group. The normal control group comprised 43 healthy volunteers and the feverish control group 46 patients with respiratory infection and fever. Venous blood was collected from each case before and after immuno globulin treatment and the level of 25-(OH)D 3 and IL-6 in the serum ��r� �����r�� ����� fl��r��c��� q����������� PCR, ��z���� linked immunosorbent assay and western blotting. Before treatment, the level of 25-(OH)D 3 in the feverish control group ��� ������c���l� l���r ���� ���� �� ��� ��r��l c���r�l �r��p, while the level of 25-(OH)D 3 in the observation group was ������c���l� �����r ���� ���� �� ��� ��r��l c���r�l �r��p. ��� level of 25-(OH)D 3 in the feverish control group was lower than the IL-6 level in the normal children, but the difference was not ��������c�ll� ������c��� (P>0.05). ��� l���l 25�(OH)D 3 in the �b��r������ �r��p ��� ������c���l� �����r ���� ��� IL�6 l���l in the normal control group. The serum content of 25-(OH) D 3 ��� ������c���l� �����r ����r ��� �r������� c��p�r�� �� before treatment levels and after treatment IL-6 level was only slightly lower. It was observed that the 25-(OH)D 3 level in the �b��r������ �r��p ��� ������c���l� ��cr����� ����r ����-noglobulin treatment and this was positively correlated with ��� ����c�� �� ��� �r�������. ��� IL�6 l���l ��� �� ������c��� changes after treatment and had little correlation with the treatment effect. The results suggested that 25-(OH)D 3 may be involved in the occurrence of Kawasaki disease in children and in the aggravation of the disease to some extent.
Introduction
Kawasaki disease (KD), also known as skin-mucosal-associated lymphoid syndrome (a vasculitis syndrome), is a rare childhood illness that affects the blood vessels (1) . The disease is most common in children and can be extremely harmful to infants. Damage may occur to coronary arteries and to the heart muscle itself (1) . Affected children may suffer from �������c ���ll ��� ����l����z�� ���c�l�r ��fl�������� ���c� can be transformed into coronary artery sustainable expansion (2), coronary artery aneurysm and even death.
The causative factors of Kawasaki disease are unknown and the disease does not appear to be hereditary or contagious. Identifying treatment for Kawasaki disease has become the focus of investigations worldwide (3) . Results obtained from prior studies (4) showed that intravenous immunoglobulin (IVIG) therapy is effective with regard to the adverse effects of Kawasaki disease, however the underlying ��c������ r������ �� b� ����r�����. S�z�k� et al (5) showed that serum 25-hydroxyvitamin D 3 [25-(OH)D 3 ] in blood ameliorates the immune system and prevents coronary artery abnormalities. Results from another related study (6) suggested that interleukin-6 (IL-6) was correlated with immunoreaction and had multiple effects such as stimulating and activating the proliferation of B cell, promoting antibody secretion, stimulating the proliferation of T cells and CTL activation (7) . IL-6 affects the expression of acute phase protein in hepatic cells, ���c� �r� ����l��� �� ��fl������r� r��c����� ��� �cc�l�r����� cell development (8) .
I� ��� pr����� �����, �� ������������ ��� ������c��c� �� serum 25-(OH)D 3 and IL-6 levels prior to and after immunoglobulin treatment in children suffering from Kawasaki disease. We aimed to provide some theoretical and practical references for the successful treatment of Kawasaki disease in children.
Materials and methods
General materials. From February, 2013 to February, 2015, 45 patients with Kawasaki disease, including 24 men and 21 women with an average age of 3.2±3 years, were enrolled in the present study, and constituted the observation group. The normal control group comprised 43 healthy volunteers during the same period. The normal control group comprised 22 men and 21 women with an average age of 2.9±2.7 years. The feverish control group comprised 46 patients (22 men and 24 women), with an average age of 3.1±2.9 years, and had respiratory infection and fever.
The aims of the study were established in accordance with relevant diagnostic criteria of Kawasaki disease presented by Japan KD Research Committee. The present study was �ppr���� b� ��� ����c� c�������� �� X�z��� C��l�r��'� Hospital. Written informed consent was obtained from the patients and/or guardians.
Methods. Venous blood (4 ml) was collected from each case prior to treatment. Samples were centrifuged at 2,000 x g for 5 ��� �� 4˚C ��� ��� �pp�r l���r �� ��� ��r�� ��� c�ll�c��� and tran���rr�� ���� � cr������c ��b� (S�z��� Alp�� B����c� Co., Ltd, S�z���, C����) ��� k�p� �� �80˚C (1) ��� ��� c������ of 25-(OH)D 3 ��� IL�6 ��r� ��r����. A���b����� ���� �� this study were purchased from Roche Diagnostics (Basel, S���z�rl���), ��� RNA �x�r�c���� k��� ��r� p�rc����� �r�� Takara Bio (Dalian, China). Patients were then treated with IVIG therapy (2 g/kg intravenous drip and oral aspirins, 2-5 days after the fever subsided). The serum was kept and the content of 25-(OH)D 3 and IL-6 was detected.
RT-polymerase chain reaction (PCR)
RNA extraction. Cryophylactic tissue samples (0.1 g) ��r� �x�r�c��� �r�� ��� l�q��� ���r���� ��� ��l��� �� �c�. S�b��q����l�, 0.45 �l �� RNA Pl�� ��� ����� ��� ��� ������� were ground in a precooled mortar and transferred into a 1.5-ml Eppendorf tube (Hamburg, Germany). After adding 0.45 ml of RNA Plus in the mortar, the samples were washed in centrifuge tube and 200 µl chloroform was then added. The samples were vigorously agitated using a vortex for 15 sec and kept on ice for 15 min. The samples were centrifuged at 8,000 x g for 15 ��� �� 4˚C ��� ��� �pp�r l���r �� ��� ��r�� ��� c�ll�c��� �� �� Epp����r� ��b� (RN�����r�����). I��pr�p���l (�q����-lent) was added to the tube and after mixing it was left on for 10 min. The samples were centrifuged again at 8,000 x g for 10 ��� �� 4˚C ��� ��� �pp�r l���r �� ��� ��r�� ��� r������. Then, 750 µl of ethyl alcohol (75%) was added and mixed ����l� ��ll���� b� ��r���r c���r��������� �� 8,000 x � �� 4˚C for 10 min. The upper layer of the serum was discarded and r������l ����l �lc���l ��� r������. ��� q��l��� �� �x�r�c��� RNA ��� ��r���� ��� RNA ��� ���r�� �� b� ���� �� r���r�� transcription.
Fluorescent quantitative PCR. Fl��r��c��� q����������� PCR k��� ��r� c�rr��� ��� �� p�r ��� ������c��r�r'� ����r�c����� (��k�r�), ���� �l���� �����c����� (��bl� I).
Enzyme-linked immunosorbent assay (ELISA).
The standard protocol for the ELISA kit was carried out, with some improvements (9) . 25-(OH)D 3 and IL-6 were diluted at a ratio of 1:40 using the assay buffer and designed the standard curve. Samples were diluted (1:100) and 80 µl of test solution and 60 µl of detection solution were added into each well (96-wells). A���r 1 � ��c�b����� �� 25˚C, �MB c�r�������c �ubstrate was added. The light absorption value was measured at 495 nm using a microplate reader (Bio-Tek Instruments Inc., Winooski, VT, USA) and the concentration of 25-(OH)D 3 and IL-6 was calculated using the standard curve.
Western blotting. An animal cell protein extraction kit was used to extract the total protein [standard protocol carried out with some improvement (10)].
Statistical analysis. We used SPSS 20.2 software (Chicago, IL, USA) for statistical analyses. Measurement data were presented as mean ± SD, and countable data were expressed by the number of cases or the percentage. Intergroup comparison was carried out using the χ 2 test. P<0.05 indicated the differ��c� ��� ��������c�ll� ������c���.
Results

25-(OH)D 3 and IL-6 levels in the serum prior to treatment.
We detected the 25-(OH)D 3 and IL-6 levels in the serum samples collected from the three groups prior to treatment with immuno globulin (Fig. 1) . The results showed that the content of serum 25-(OH)D 3 in the feverish control group was lower than that of the normal control group. By contrast, the level of serum 25-(OH)D 3 in the observation group was higher than that of the normal control group. The differences were ��������c�ll� ������c��� (P<0.05). ��� l���l �� ��r�� 25-(OH) D 3 in the feverish control group was lower than that of serum IL-6 in the normal children, but there were no statistically ������c��� �����r��c�� (P>0.05). ��� l���l �� ��r�� 25-(OH) D 3 in the observation group was higher than the content of serum IL-6 in the normal children, and the difference was ��������c�ll� ������c��� (P<0.05). ��� 25-(OH)D 3 and IL-6 gene expression levels in the three groups prior to treatment with immunoglobulin showed the same pattern observed in the protein expression (Fig. 2) .
25-(OH)D 3 and IL-6 gene expression levels after immunoglobulin treatment.
We measured 25-(OH)D 3 and IL-6 gene expression levels in the three groups after immunoglobulin treatment (Table II) and observed a significant increase in serum 25-(OH)D 3 levels compared with the levels prior to treatment and the differences were statistically significant ��bl� I. Fl��r��c��� q����������� PCR pr���r�. (P<0.05). In the observation group, after immunoglobulin treatment, the IL-6 level in serum was lower compared with the level before treatment, albeit the difference was not statistically ������c��� (P>0.05). ��� IL�6 l���l �� ��� �b��r������ �r��p ����r ������ �l�b�l�� �r������� ��� �� ������c��� �����r��c� compared to that in the normal control and feverish control �r��p� (P>0.05). ��� 25-(OH)D 3 and IL-6 expression levels were measured using western blotting (Fig. 3) . The results were comparable to those obtained from ELISA and RT-PCR. 3 and IL-6 expression in the observation group prior to and after treatment. Before treatment, levels of 25-(OH)D 3 and IL-6 in the observation group were positively correlated (R 2 =0.9563) (Fig. 4A) . However, no ������c��� c�rr�l����� ��� ����bl����� ��r l���l� ����r �r���-ment of 25-(OH)D 3 and IL-6 (Fig. 4B) .
Correlation between 25-(OH)D
Correlation between 25-(OH)D 3 and IL-6 and the disease course in the observation group.
Our results showed that the pathogenic condition of patients in the observation group was aggravated with time and the level of 25-(OH)D 3 , and also increased with time whereas the content of IL-6 protein remained unchanged in the course of the disease (Fig. 5) .
Discussion
Kawasaki disease is a serious threat to infant health and growth (11) . Related data (12) have shown that despite advances in studies and treatment of Kawasaki disease, the exact pathogenesis of this disease remains to be determined and there is therefore no effective treatment method that can b� ���l�z�� (13) . I� ��� b��� ����� ���� � c�ll� �� p������� ���� Kawasaki disease are abnormally active (14) . Additionally, it has been established that T cells, to a large extent, can enhance ��� �������� ��� ��pr��� ��� �r������'� r�������c� ������� various illnesses (15) . The results obtained from related studies have shown that the overactive T cell can interact with mononuclear cells and stimulate the overexpression of different c���k���� ��� ��fl������r� ��b����c�� ���� c�� ������ ��� blood vessels (16, 17) . To shed some light on the subject of the p����������� �� K�����k� �������'�, �� �� �x�r���l� ��p�r���� to investigate any possible connection between this disease and the level of cytokines. Vitamin D is an important signal molecule in human body that is involved in the regulation of cellular signal substances such as calcium and phosphorus, cytomembrane elements, and immunoreaction such as inhibiting the abnormal proliferation of body T/B lymphocyte (18) . Kudo et al (4) demonstrated that in coronary endothelial cells, 25-(OH)D 3 inhibited the release of IL-8 and the expression of cell adhesion molecule-1 induced by TNF-α. However, it could not affect the level of IL-6. It has b��� ����� ���� � �p�c��c ������ �� 25-(OH)D 3 is needed for r���l����� KD c�r���r� �r��r� ��fl�������� (19) .
By measuring the 25-(OH)D 3 and IL-6 mRNA and protein in different groups prior to treatment, we showed that serum 25-(OH)D 3 and IL-6 levels in the feverish control group were ������c���l� l���r ���� ����� �� ��� ��r��l c���r�l �r��p. 
